Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
21 Marzo 2024 - 6:00AM
Business Wire
Collaboration provides phase-appropriate
plasmid DNA to support the development of engineered stem cells for
cancer therapy
Charles River Laboratories International, Inc. (NYSE: CRL) and
National University of Singapore’s (NUS) Yong Loo Lin School of
Medicine (NUS Medicine), a leading medical education institution
with a world-renowned medical research field of stem cell biology
and therapy, today announced a High Quality (HQ) plasmid DNA
development and manufacturing agreement.
NUS Medicine will utilize Charles River’s market leading
contract development and manufacturing organization (CDMO)
expertise in HQ and GMP- compliant plasmid DNA, which serves as a
critical starting material for its engineered stem cell cancer
therapy and builds on a historic provision of research grade
plasmid.
Phase-Appropriate Plasmid Solutions
NUS Medicine will leverage this collaboration to access Charles
River’s center of excellence, and established manufacturing
platform, eXpDNA™.
In recent years, Charles River has significantly expanded its
cell and gene therapy portfolio to streamline complex supply chains
and meet growing demand for plasmid DNA, viral vector, and cell
therapy services. Combined with the Company’s legacy testing
capabilities, Charles River offers an industry-leading “concept to
cure” advanced therapeutic solution.
Available on-demand is a 30-minute case study webinar led by Dr.
Andrew Frazer, Associate Director, Scientific Solutions, Gene
Therapy CDMO Services, that explores the role of plasmid DNA as a
critical starting material, the latest advancements in associated
regulatory guidance to safeguard your therapeutic programs, and
case studies demonstrating expedited development and manufacture of
ATMPs: https://bit.ly/3Ii5wcZ
Approved Quote
- “We are thrilled to continue our work with NUS Medicine and
support their important work developing engineered stem cells for
cancer therapy. Charles River has had decades of success
manufacturing, and reliably delivering plasmid DNA as both a
critical starting material and drug product, helping to safeguard
our customer programs.” - Kerstin Dolph, Corporate Senior Vice
President, Biologics Solutions, Charles River
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240321995828/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com Charles River Media Contact: Amy
Cianciaruso Corporate Vice President, Chief Communications Officer
781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Charles River Laboratories (NYSE:CRL)
Gráfica de Acción Histórica
De May 2023 a May 2024